Flinton Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Flinton Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,376	Closed	-$71K	–	922
2018 Q3	$71K	Buy	11,376 +816	+8%	+$6.27K	﹤0.01%	816
2018 Q2	$85K	Hold	10,560	–	–	﹤0.01%	785
2018 Q1	$79K	Buy	10,560 +2,480	+31%	+$16.5K	﹤0.01%	787
2017 Q4	$48K	Buy	8,080 +2,048	+34%	+$12.4K	﹤0.01%	815
2017 Q3	$44K	Buy	6,032 +1,456	+32%	+$9.25K	﹤0.01%	814
2017 Q2	$31K	Buy	4,576 +2,448	+115%	+$18.1K	﹤0.01%	822
2017 Q1	$20K	Buy	+2,128	New	+$21.2K	﹤0.01%	826

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Flinton Capital Management's PGNX Position: Q4 2018 in Review

Flinton Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 11,376 shares — an estimated $71K sold.

Flinton Capital Management first reported a position in PGNX in Q1 2017 and held it in 7 quarters. The position peaked at $85K in Q2 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

Flinton Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
Flinton Capital Management sold 11,376 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $71K.
Flinton Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
Flinton Capital Management's Progenics Pharmaceuticals Inc position peaked at $85K in Q2 2018.
150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Flinton Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.